BAY 1895344 is a potent and highly selective inhibitor of the ATR kinase, which is involved in the DNA damage response. Further disruption of the DNA damage response via ATR inhibition is expected to induce synthetic lethality in cancers with already impaired DNA damage repair mechanisms. The Bayer team was able to overcome poor solubility in [...]
< 1 minute read
Sep. 18, 2021
BAY 1895344: A Selective Oral ATR Kinase Inhibitor
BAY 1895344
selective oral ATR kinase inhibitor in Ph. I for adv. solid tumors and lymphomas from HTS and modeling on PI3Kg structure J. Med. Chem., Jun. 5, 2020 Bayer AG, Berlin, DE